OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 2026
14.6.2026 11:00:00 EEST | Business Wire | Press release
OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice.
In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1
“The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurrency of respiratory infections is an important medical issue with severe impacts for patients. This extensive evidence in a real world setting strongly reinforces existing clinical data and should give physicians greater confidence that they have the possibility to address RTI recurrence, relieving patient burden.”
Recurrent RTIs impose a profound, dual burden: for patients, they mean persistent illness, missed days of school or work, and a significantly diminished quality of life.3-5 On a societal level, recurrent RTIs drive a high volume of medical visits, strain healthcare infrastructure, and remain a primary catalyst for antibiotic prescription.3-6 Antibiotic overprescription is fuelling the global antimicrobial resistance crisis.7
Vildana Mujkić, Board Member and Eastern European Alliance Leader, Global Allergy & Airways Patient Platform (GAAPP), stated:
“For individuals living with recurrent respiratory infections, prevention is not just a clinical objective-it is key to reducing their overall disease burden. This study provides valuable real-world evidence demonstrating how preventive strategies can meaningfully lower infection rates. Patients and families need solutions that enable healthier, more active lives, and research like this helps advance more informed, patient-centred care.”
The REACH study findings, which show that Broncho-Vaxom® leads to a reduction in RTI recurrence that required medical visits, directly support the EAACI 2026 theme, “Vision Zero: A Future Free from Allergy and Asthma Burden.” Because respiratory infections are among the most common triggers for asthma exacerbations and chronic airway inflammation, identifying effective, non-antibiotic strategies to address frequent RTIs is a critical step toward helping to achieve “Vision Zero” and lifting the systemic burden of respiratory diseases worldwide.8
The second primary endpoint evaluating matched, untreated cohorts within real-world data sets is under analysis and will be released later this year.
About recurrent RTIs
Recurrent RTIs are a major global health burden.4,9 Beyond their clinical impact, respiratory tract infections generate significant healthcare and societal costs, largely driven by frequent medical visits and lost productivity.5,10-12 These findings show that Broncho-Vaxom® helps reduce infection frequency and decrease the need for physician visits, supporting its role as a preventive option in routine clinical practice.
About the real-world REACH study
OM Pharma’s REACH (Real-World Evidence study of OM-85 in Adults and Children in CHina, Italy, and Belgium) study is a multi-country, non-interventional cohort study that used secondary data extracted from healthcare databases in two European countries (THIN Belgium and THIN Italy) and China (Inspur).2 This means that the data analysed were not collected specifically for evaluating routine practice or the effectiveness of Broncho-Vaxom®. Instead, medical records generated during routine care in primary, secondary, or tertiary settings were later extracted and analysed. This is the largest RWE study on this product to date. The preliminary results are consistent with previous clinical studies demonstrating the preventive effects of Broncho-Vaxom®, extending this evidence to broader, real-world populations covering its large indication.
About Broncho-Vaxom® (OM-85)
Broncho-Vaxom® is a therapy derived from selected and inactivated bacterial strains that train and strengthen the immune system to prevent recurrent respiratory infections. OM-85 has been proven to help reduce the incidence and severity of recurrent respiratory tract infections (RTIs) in children and adults and is being currently tested for potential beyond these uses, for example, in chronic conditions such as asthmaor wheezing.13 In 2025, over 5 million people were reached with Broncho-Vaxom®.14 It is currently registered in 69 countries worldwide for the prevention of recurrent RTIs in children and adults. Broncho-Vaxom® is also commercialised in other countries under different brand names, including Broncho‑Munal®, Ommunal® and Paxoral®.
About OM Pharma
OM Pharma is pioneering a new standard of care for patients suffering from frequent infections. The company develops innovative bacterial lysate therapies designed to strengthen the immune system. By training the body's natural defences, these therapies help patients fight infections that keep coming back. Headquartered in Geneva, OM Pharma operates an integrated biotech campus that brings together research and development, manufacturing, and distribution. Drawing on 90 years of expertise, OM Pharma serves patients in more than 100 countries and reaches approximately 16 million people worldwide.
References:
- Canonica GW, Maffert P, Sansone C, Ouillon J, Lehr L, Zheng J, Price D. Effectiveness of Broncho-Vaxom® in Preventing Recurrent Respiratory Tract Infections: Preliminary Findings from REACH, a Multi-Country Real-World Study. Abstract presented at: European Academy of Allergy & Clinical Immunology; June 14, 2026. Abstract reference number: 100283 and Flash Talk (data on file) https://eaaci2026.process.y-congress.com/ScientificProcess/schedule/?sessionGuid=cb0d9ef6-6755-46fe-82eb-9682e4f3d30e&setLng=en
- European Medicines Agency. REACH study: Real-World Evidence study of OM-85 in Adults and Children in China, Italy, and Belgium | HMA-EMA Catalogues of real-world data sources and studies. Europa.eu. Updated March 20, 2026. Accessed May 18, 2026. https://catalogues.ema.europa.eu/node/4217/administrative-details
- Schot MJC, Dekker ARJ, van Werkhoven CH, et al. Burden of disease in children with respiratory tract infections in primary care: diary-based cohort study. Family Practice. 2019;36(6):723-729. doi:https://doi.org/10.1093/fampra/cmz024
- Reed KD. Respiratory Tract Infections. Molecular Medical Microbiology. Published online 2015:1499-1506. doi:https://doi.org/10.1016/b978-0-12-397169-2.00084-6
- Zhang S, Wahi-Singh P, Wahi-Singh B, Chisholm A, Keeling P, Nair H. Costs of management of acute respiratory infections in older adults: A systematic review and meta-analysis. Journal of Global Health. 2022;12. doi:https://doi.org/10.7189/jogh.12.04096
- Fleming-Dutra KE, Hersh AL, Shapiro DJ. Prevalence of Inappropriate Antibiotic Prescriptions Among US Ambulatory Care Visits, 2010-2011. JAMA. 2016;315(17):1864. doi:https://doi.org/10.1001/jama.2016.4151
- Antimicrobial Resistance Collaborators. Global Burden of Bacterial Antimicrobial Resistance in 2019: a Systematic Analysis. The Lancet. 2022;399(10325):629-655. doi:https://doi.org/10.1016/S0140-6736(21)02724-0
- Busse WW, Lemanske RF Jr, Gern JE. Role of viral respiratory infections in asthma and asthma exacerbations. Lancet. 2010;376(9743):826-834. doi:10.1016/S0140-6736(10)61380-3
- Jin X, Ren J, Li R, et al. Global burden of upper respiratory infections in 204 countries and territories, from 1990 to 2019. EClinicalMedicine. 2021;37:100986. doi:https://doi.org/10.1016/j.eclinm.2021.100986
- Zhang S, Akmar LZ, Bailey F, et al. Cost of Respiratory Syncytial Virus-Associated Acute Lower Respiratory Infection Management in Young Children at the Regional and Global Level: A Systematic Review and Meta-Analysis. J Infect Dis. 2020;222(Suppl 7):S680-S687. doi:10.1093/infdis/jiz683
- Fendrick AM, Monto AS, Nightengale B, Sarnes M. The economic burden of non-influenza-related viral respiratory tract infection in the United States. Arch Intern Med. 2003;163(4):487-494. doi:10.1001/archinte.163.4.487
- Schuez-Havupalo L, Toivonen L, Karppinen S, Kaljonen A, Peltola V. Daycare attendance and respiratory tract infections: a prospective birth cohort study. BMJ Open. 2017;7(9):e014635. Published 2017 Sep 5. doi:10.1136/bmjopen-2016-014635
- Esposito S, Soto-Martinez ME, Feleszko W, Jones MH, Shen KL, Schaad UB. Nonspecific immunomodulators for recurrent respiratory tract infections, wheezing and asthma in children: a systematic review of mechanistic and clinical evidence. Current Opinion in Allergy and Clinical Immunology. 2018;18(3):198-209. doi:https://doi.org/10.1097/ACI.0000000000000433
- OM Pharma. Data on file.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260614793154/en/
Contacts
Media Contacts:
Sara Webber
Corporate Communications, OM Pharma
Media@ompharma.com I +41 79 511 23 30
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Canada to Join the NATO Innovation Fund to Advance the Local Defence, Security and Resilience Ecosystem21.11.2026 18:00:00 EET | Press release
Canada announced today it is joining the NATO Innovation Fund, becoming the 25th Allied nation to commit to backing deep tech innovation to address the needs of NATO nations. The Government of Canada is committing EUR 64,590,000 (approximately CAD $100 million) to the firm, with the Business Development Bank of Canada (BDC) holding and managing Canada’s investment in the Fund. This brings total commitments to the NATO Innovation Fund to more than EUR 1.1 billion. Canadian membership will give domestic innovators access to patient capital, opportunities to accelerate the adoption of their technology by governments and businesses across the Alliance, a large network of co-investors, and lessons learned from the NIF’s work to date across 24 participating nations. “Canada has the talent, the innovation, and the ambition to be a global leader in defence and security. The NATO Innovation Fund is helping turn that potential into real capabilities by connecting Canadian innovators with the inv
Persona Earns CEN/TS 18099 High Certification for Injection Attack Detection21.11.2026 16:30:00 EET | Press release
Persona, the leading global identity platform, today announced that its Android SDK has earned CEN/TS 18099 High certification for injection attack detection (IAD). High certification is the top level of the European standard. The evaluation was run by CLR CERT, the certification body of Cabinet Louis Reynaud (CLR) Labs. CLR Labs is accredited under ISO/IEC 17025, the international standard for testing laboratories, and it edits CEN/TS 18099. This certificated injection attack detection is available to all Persona customers and can be activated by working with Persona's team. Injection attacks skip the camera entirely. Instead of holding a photo or mask up to a lens, fraudsters use virtual cameras, emulators and tampered devices to feed stolen, manipulated, or AI-generated media straight into the verification flow. To the system, the result looks like a real live capture, and traditional liveness checks aren't built to catch it. "Our customers are facing more sophisticated deepfakes, f
Verlinvest to Facilitate China Resources’ Full Exit From Oatly20.11.2026 23:30:00 EET | Press release
Verlinvest, the global, family-backed consumer-focused evergreen investment company, today announced it has entered into an agreement to acquire China Resources Enterprise, Limited’s (“China Resources”) indirect interests in Oatly Group AB (publ) (Nasdaq: OTLY) (“Oatly”), the world’s original and largest oat drink company. The transaction builds on Verlinvest’s investment in Oatly since 2016 and reinforces its conviction in the company’s long-term potential. A change in strategic direction of state-owned enterprise China Resources informed its decision to fully exit its investment in Oatly. China Resources worked constructively with Verlinvest to identify the best path for it to do so in recognition of the complexity of their joint holding structure. Under the agreement, Verlinvest will acquire China Resources’ indirect interests in Oatly’s equity and convertible instruments that are currently held through Verlinvest and China Resources’ joint venture vehicle, Nativus Company Limited.
Picsart Opens the AI Behind Its Platform to Developers & Businesses20.11.2026 21:54:00 EET | Press release
Picsart, the AI media production and distribution platform backed by Sequoia Capital and SoftBank Vision Fund 2, today launched Picsart Platform - a multimodal creative AI hub that gives developers the technology behind the platform used by more than 100 million people each month. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261120520968/en/ Picsart Opens the AI Behind Its Platform to Developers & Businesses. They can now build their own video, audio, image features using 250+ models from 30+ providers, alongside Picsart's own editing models, through one API, CLI or MCP server. As new video and image models launch every few weeks, managing separate APIs, API keys, and billing systems creates a fragmented ecosystem. By offering unified access to creative tools, Picsart Platform eliminates fragmentation for all creators, spanning independent developers and corporate marketing teams and studios, by providing access to over 25
NetJets Becomes Official Private Aviation Provider of the Hahnenkamm Races in Kitzbühel20.11.2026 19:45:00 EET | Press release
NetJets, the global leader in private aviation, is delighted to announce its newest partnership with the Hahnenkamm Races in Kitzbühel, Austria, becoming the event's Official Private Aviation Provider. The Hahnenkamm Races are among the most prestigious and celebrated events in world alpine skiing. They attract athletes, business leaders, international guests and winter sports enthusiasts from around the world. Through this partnership, NetJets and the Hahnenkamm Races are aligning two brands renowned for excellence, precision and world-class experiences. The partnership is an exciting addition to NetJets' growing portfolio of premium lifestyle and sporting partnerships, offering Owners unique opportunities to access one of Europe's most iconic winter sporting events. Alongside premium hospitality and unforgettable behind-the-scenes experiences, the collaboration will help create extraordinary moments for Owners, both in the air and on the ground in Kitzbühel. “Kitzbühel is synonymous
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom